ImprimisRx NJ, Ledgewood, NJ

Is ImprimisRx NJ registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does ImprimisRx NJ hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Colorado State Board of Pharmacy also lists nonresident license OSP 6358 for ImprimisRx NJ, LLC dba ImprimisRx, Ledgewood, NJ, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018755 for IMPRIMISRX NJ LLC, LEDGEWOOD, NJ, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002089 for IMPRIMIS RX NJ, LLC (dba IMPRIMIS RX), LEDGEWOOD, NJ, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001462 for ImprimisRx NJ, LLC (dba ImprimisRx), LEDGEWOOD, NJ, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012137 for ImprimisRx NJ, LLC, Ledgewood, NJ, status Active, as of Nov 10, 2026.

Has ImprimisRx NJ had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (May 26, 2023) for ImprimisRx NJ. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 2 actions: “Through a disciplinary action of the Board, the license is voluntarily surrendered, subject to terms and conditions in the decision” dated Feb 1, 2026, case AC 7456 on nonresident license NRP 2062 and “Through a disciplinary action of the Board, the license is voluntarily surrendered, subject to terms and conditions in the decision” dated Feb 1, 2026, case AC 7456 on nonresident license NSC 101151. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Stipulation” dated Jul 28, 2015, case 2015-1867 on nonresident license OSP 6358. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Reprimand” dated Sep 18, 2023, case 2020003085 on nonresident license 054018755 and “Fine” dated Sep 18, 2023, case 2020003085 on nonresident license 054018755.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
ImprimisRx NJ
Location
Ledgewood, NJ
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
May 26, 2023
FDA Data Dashboard inspections
0 inspections; 0 published Form 483s
Form 483 text on this page
1 Form 483, 9 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as ImprimisRx NJ, a 503A facility, with 3 dated actions.

Document
May 26, 2023Warning letterWarning Letter (05/26/2023)FDA copy (archived)
Aug 5, 2022Form 483483 Issued 08/05/2022FDA copy (archived)
Apr 9, 2019Form 483483 Issued 04/09/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists ImprimisRx NJ LLC, Ledgewood, NJ (FEI number 3003348498), matched to this page by exact name, city and state. It lists no classified inspection under this name at that site. Dashboard firm profile.

Form 483s FDA has published for this site

No published Form 483 for FEI 3003348498 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 11, 2022 to Aug 5, 2022: 9 observations

Firm on the cover
ImprimisRx NJ, 1705 Route 46 West, Ste 4, Ledgewood, NJ 07852-9720
FEI number
3003348498
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

The ISO 5 classified aseptic processing areas had visibly dirty equipment or surface.

Specifically, on July 11, 2022, we observed dark orange staining on the HEPA filters in the back of the <Redacted B4> LAFH-NJ-LAFH <Redacted B4> in the sterile production suite filling room. These HEPA filters supply the ISO 5 classified production area with <Redacted B4> HEPA airflow. On July 29, 2022, we observed the production of "EDETATE DISODIUM INJECTION", lot 07292022@<Redacted B4>. In this hood and noted that the discoloration was not removed prior to, during, or after production. Additionally <Redacted B4> batches of products produced within this hood from February 8, 2022 to July 8, 2022, and currently within expiry, have been distributed under respective prescriptions. For example, see the table below for prescriptions distributed for three different batches.

Product Batch Number Rx Numbe rs ASCORBIC ACID (NON-CORN SOURCE) PF 100ML SOL BATCH (500)MG/ML lNJECTABLE

Redacted B4 <Redacted B4 I

_l_

VITAMIN B-COMPLEX PRESERVATIVE-FREE 100MG-2MG-2MG-100MG-2MG lNJECTABLE

Redacted B4 I

DMPS SODIUM PF 50 MG/ML lNJECTABLE 50 MG/ML lNJECTABLE

Redac ted B4 I

Observation 2

Personnel did not disinfect and change gloves frequently enough to prevent contamination.

Specifically, on July 12, 2022, production technician <Redacted B4> was observed multiple times using <Redacted B4> gloved hand to handle items outside of ISO 5 classified <Redacted B4> LAFW hood NJ-LAF <Redacted B4> and then subsequently handling items inside the hood without re-sanitizing gloves. For example, in two instances, <Redacted B4>, sprayed <Redacted B4> hands with <Redacted B4> then grabbed onto a chair and then reinsert <Redacted B4> hand underneath the ISO 5 hood handling products without re-sanitizing gloves. In another instance, <Redacted B4> sprayed gloved hands with <Redacted B4>, then moved the plastic bin containing the empty eye drop vials and then went right underneath the ISO 5 hood to handle products, again, without re-sanitizing <Redacted B4> gloves with <Redacted B4>. These occurred during the production of"TIMOLOL -BRIMONIDINE -DORZOLAMIDE P-F OPTH 0.5/0.15/2) % SOLUTION", lot 07122022@ <Redacted B4>

Observation 3

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, during the production of"TIMOLOL -BRIMONIDINE-DORZOLAMIDE P-F OPTH (0.5/0.15/2) % SOLUTION" ophthalmic drops, lot 07122022@ <Redacted B4> and "EDTA DISODIUM PF 150 MG/ML INJECTABLE", lot 07292022 <Redacted B4> on July 12 and 29, 2022, respectively, production technician {b)(eJ inadequately sanitized items before bringing them from the ISO 7 classified filling room into the respective ISO 5 classified hood. The items, such as bagged vials, bottles, and caps, were sprayed with <Redacted B4> while <Redacted B4> atop a stainless-steel table, placing sanitized surfaces back onto the tabletop as the opposite sides were sprayed, and they were not sprayed or wiped again before crossing the threshold into the higher classification space. The stainless-steel table was sanitized immediately prior to production and utilized repeatedly for the purpose of sanitizing items over the course of the batch production, lasting approximately a few hours.

Observation 4

The use of sporicidal agents in the cleanrooms and ISO 5 classified aseptic processing area was inadequate.

A. The interior ceiling of the ISO 5 classified <Redacted B4> LAFH, hood NJ-LAFH <Redacted B4> was not cleaned at any point during the <Redacted B4> cleaning process witli a sporicidal or sanitizing agent. Production technicians <Redacted B4> and <Redacted B4> explained that the surface is not ever cleaned or wiped, including the "plastic" grate covering the HEPA Ilters, as explained <Redacted B4>

B. On July 27, 2022, while production technician <Redacted B4> was cleaning the walls of the ISO 7 classified filling room with a mop head and either a detergent or sporicidal agent, he mopped around areas where items were protruding (i.e. fire alarm, outlet covers, and door handle) and not the items themselves. Those items were not cleaned at any point in the <Redacted B4> cleaning process. <Redacted B4> later explained that the protruding items should be cleaned during the <Redacted B4> cleaning process.

C. During the <Redacted B4> cleaning process of the ISO 7 classified filling room on July 27, 2022, floor coving was not cleaned with a detergent or sporicidal agent. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 5

Your facility design allowed the influx of poor quality air into a higher classified area.

Observation 6

The segregated production areas surrounding the ISO 5 classified aseptic processing area contained dust-collecting overhangs without adequate and frequent cleaning.

Specifically,

A. On July 11 , 2022, we observed two fire extinguishing sprinkler system heads, located in the ceiling of the ISO 7 classified filling room, hanging down from the ceiling, which creates difficult to clean surfaces around the objects protruding from the ceiling tiles.

B. The ceiling of the ISO 7 classified production area contains difficult to clean surfaces. On July 11, 12, and 13, 2022, we observed fiber-like particles, approximately a couple inches in length each, hanging from ceiling of the ISO 7 classified filling room and ISO 7 classified gowning room. On July 27, 2022, while production technician <Redacted B4> was cleaning the ceiling of the ISO 7 classified filling room, caulking from the ceiling tiles, approximately a couple inches in length each, started to peel away in fom instances. In two of these instances, the pealed caulking was pushed back intact with the mop head, and in two cases the caulking peeled away and fell to the floor in the ISO 7 classified filling room.

Observation 7

Non-microbial contamination was observed in your production area.

Specifically,

B. There is no assurance that your cleaning process removes product and cleaning agent residue from your reusable glassware and utensils used in sterile production areas. Your support technician <Re d acted B4> s tated on July 12, 2022, that no measurements are used to crea

te the • diluted solution of <Re da cted B4> detergent, which is utilized, with a household sponge, to clean all reusable parts for sterile produc tion, and then rinsed with a <Redacted B4> mixture.stated <Redacted B4> prepares the detergent solution approximately <Redacted B4> and has prepared <Redacted B4> without measurem ents for approximately two years. Per t he detergent bottle direc tions, <Redacted B4>. All sizes of graduated cylinders undergo <Redacted B4> washing and are not autoclaved prior to use in production operations. Graduated cylinders are utilized in the production of all your sterile products such as ophthalmic drops and injectable solutions. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 8

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, hard gel capsules used during the production of <Redacted B4> "PENTOSAN POLYSULFATE SODIUM 150 MG DR CAPSULE", lot# 07122022® <Redacted B4> were at different heights when loaded into the capsule machine, and subsequently filled to different heights with the drug mixture. Approximately 26 out 41 capsules were filled to a noticeably lower height of <Redacted B4> volume than the others. Your PIC explained that <Redacted B4> fill volume directly correlates with drug product potency.

Observation 9

ISO 5 classified areas were not certified under dynamic conditions.

Specifically, unidirectional airflow was not verified under dynamic operational conditions representative of your typical aseptic processing practices. Air visualization studies ("smoke studies") performed in two ISO 5 classified laminar airflow hoods (LAFH) and one ISO 5 classified biological safety cabinet (BSC), conducted on Febmaiy 4, 2022, did not demonstrate unidirectional airflow, for example, around equipment and components, such as vials and bottles, observed during sterile production operations on July 12 and 29, 2022. Also, equipment and materials are placed too close to the respective HEPA grate or air intake openings at the back of the hood's work surface, which compromises unidirectional airflow.

In recording "LFH <Redacted B4>" DYNAMIC SMOKE STUDY", conducted in <Redacted B4> airflow NJ-LAFH <Redacted B4> smoke is seen flowing pward and in a back current (time <Redacted B4>), creating non-laminar airflow in the critical zone including immediately behind and to the right of the <Redacted B4> filling station. ...

Read the full 483 (Internet Archive copy FDA links)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6358OSPImprimisRx NJ, LLC dba ImprimisRxLedgewood, NJActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018755LICENSED PHARMACYIMPRIMISRX NJ LLCLEDGEWOOD, NJACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002089NONRESIDENT PHARMACYIMPRIMIS RX NJ, LLC (dba IMPRIMIS RX)LEDGEWOOD, NJACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001462Non Resident PharmacyImprimisRx NJ, LLC (dba ImprimisRx)LEDGEWOOD, NJActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301012137PharmacyImprimisRx NJ, LLCLedgewood, NJActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.